Skip to main content
Top
Published in: European Radiology 6/2011

Open Access 01-06-2011 | Nuclear Medicine

PET/CT without capacity limitations: a Danish experience from a European perspective

Authors: Poul Flemming Høilund-Carlsen, Oke Gerke, Mie Holm Vilstrup, Anne Lerberg Nielsen, Anders Thomassen, Søren Hess, Mette Høilund-Carlsen, Werner Vach, Henrik Petersen

Published in: European Radiology | Issue 6/2011

Login to get access

Abstract

Objectives

We report the 3-year clinical experience of a large new Danish PET/CT centre without capacity limitations in relation to national and European developments.

Methods

The use of PET/CT in cancer was registered from early 2006 to early 2009 to judge the impact on patient management and to compare it with national and European trends.

Results

6056 PET/CT examinations were performed in 4327 patients. Activity increased by 86 examinations per month compared with the same month the year before. Referrals came primarily from oncology (23.0%), haematology (21.6%), surgery (12.6%), internal medicine (12.7%) and gynaecology (5.5%). Referral indications were diagnosis (31.3%), staging (22.3%), recurrence detection (21.2%), response evaluation (17.0%) and other (8.2%). Response from nearly 60% of users showed that PET/CT caused a change in diagnosis and/or staging and/or treatment plan in 36.0% of cases. During the study period, there was a steep increase in the national use of FDG and in the European use of PET/CT.

Conclusions

We recorded a constantly increasing use of PET/CT that caused a change in diagnosis and/or staging and/or treatment plan in 36.0% of cases. In line with national and European trends this may suggest a shift in favour of functional rather than anatomical imaging.
Literature
2.
go back to reference Hillner BE, Liu D, Coleman RE, Shields AF et al (2007) The National Oncologic PET Registry (NOPR): design and analysis plan. J Nucl Med 48:1901–1098PubMedCrossRef Hillner BE, Liu D, Coleman RE, Shields AF et al (2007) The National Oncologic PET Registry (NOPR): design and analysis plan. J Nucl Med 48:1901–1098PubMedCrossRef
3.
go back to reference Podoloff DA, Advani RH, Allred C et al (2007) NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Cancer Netw 5(Suppl 1):S1–S22 Podoloff DA, Advani RH, Allred C et al (2007) NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Cancer Netw 5(Suppl 1):S1–S22
4.
go back to reference Boellaard R (2009) Standards for PET image acquisition and quantitative data analysis. J Nucl Med 50:11S–S20PubMedCrossRef Boellaard R (2009) Standards for PET image acquisition and quantitative data analysis. J Nucl Med 50:11S–S20PubMedCrossRef
5.
go back to reference Boellaard R, O’Doherty MJ, Weber WA et al (2010) FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 37:181–200PubMedCrossRef Boellaard R, O’Doherty MJ, Weber WA et al (2010) FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 37:181–200PubMedCrossRef
6.
go back to reference Allen-Auerbach M, Weber WA (2009) Measuring response with FDG-PET: methodological aspects. Oncologist 14:369–377PubMedCrossRef Allen-Auerbach M, Weber WA (2009) Measuring response with FDG-PET: methodological aspects. Oncologist 14:369–377PubMedCrossRef
8.
go back to reference Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 50:122S–150SPubMedCrossRef Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 50:122S–150SPubMedCrossRef
9.
go back to reference Långström B, Bergström M, Antoni G, Engler E (2001) Uppsala University PET Centre 1989–2001. Uppsala University PET Centre, Uppsala Långström B, Bergström M, Antoni G, Engler E (2001) Uppsala University PET Centre 1989–2001. Uppsala University PET Centre, Uppsala
11.
go back to reference Rodell A (2003) On the trail of inner life. PET in Århus 1993–2003. Århus PET Center, Århus Rodell A (2003) On the trail of inner life. PET in Århus 1993–2003. Århus PET Center, Århus
13.
go back to reference European Association of Nuclear Medicine (2006) Status of nuclear medicine in Europe–2006. EANM’06 statistics survey. EANM, Vienna European Association of Nuclear Medicine (2006) Status of nuclear medicine in Europe–2006. EANM’06 statistics survey. EANM, Vienna
14.
go back to reference European Association of Nuclear Medicine (2007) Status of nuclear medicine in Europe–2007. EANM’07 statistics survey. EANM, Vienna European Association of Nuclear Medicine (2007) Status of nuclear medicine in Europe–2007. EANM’07 statistics survey. EANM, Vienna
15.
go back to reference European Association of Nuclear Medicine (2009) Status of nuclear medicine in Europe–2009. EANM’09 statistics survey. EANM, Vienna European Association of Nuclear Medicine (2009) Status of nuclear medicine in Europe–2009. EANM’09 statistics survey. EANM, Vienna
17.
go back to reference Tucker R, Coel M, Ko J, Morris P, Druger G, McGuigan P (2001) Impact of fluorine-18 fluorodeoxyglucose positron emission tomography on patient management: first year’s experience in a clinical center. J Clin Oncol 19:2504–2508PubMed Tucker R, Coel M, Ko J, Morris P, Druger G, McGuigan P (2001) Impact of fluorine-18 fluorodeoxyglucose positron emission tomography on patient management: first year’s experience in a clinical center. J Clin Oncol 19:2504–2508PubMed
18.
go back to reference Gutte H, Højgaard L, Kjær A (2005) Early clinical experience and impact of 18F-FDG PET. Nucl Med Commun 16:989–994CrossRef Gutte H, Højgaard L, Kjær A (2005) Early clinical experience and impact of 18F-FDG PET. Nucl Med Commun 16:989–994CrossRef
19.
go back to reference Gopalan D, Griffiths D, Townsend C, Prvulovich E, Bomanji J, Costa DC, Ell PJ (2002) Fluorodeoxyglucose positron emission tomography in clinical oncology: the referrer’s perspective. Nucl Med Commun 23:1041–1046PubMedCrossRef Gopalan D, Griffiths D, Townsend C, Prvulovich E, Bomanji J, Costa DC, Ell PJ (2002) Fluorodeoxyglucose positron emission tomography in clinical oncology: the referrer’s perspective. Nucl Med Commun 23:1041–1046PubMedCrossRef
20.
go back to reference Hillner BE, Tunuguntla R, Fratkin M (2004) Clinical decision associated with positron emission tomography in prospective cohort of patients with suspected or known cancer at one United States center. J Clin Oncol 22:4147–4156PubMedCrossRef Hillner BE, Tunuguntla R, Fratkin M (2004) Clinical decision associated with positron emission tomography in prospective cohort of patients with suspected or known cancer at one United States center. J Clin Oncol 22:4147–4156PubMedCrossRef
21.
go back to reference Lau WF, Binns DS, Ware RE, Ramdave S, Cachin F, Pitman AG, Hicks RJ (2005) Clinical experience with the first combined positron emission tomography/computed tomography scanner in Australia. Med J Aust 182:172–176PubMed Lau WF, Binns DS, Ware RE, Ramdave S, Cachin F, Pitman AG, Hicks RJ (2005) Clinical experience with the first combined positron emission tomography/computed tomography scanner in Australia. Med J Aust 182:172–176PubMed
22.
go back to reference Hillner BE, Siegel BA, Liu D et al (2008) Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET registry. J Clin Oncol 26:2155–2161PubMedCrossRef Hillner BE, Siegel BA, Liu D et al (2008) Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET registry. J Clin Oncol 26:2155–2161PubMedCrossRef
23.
go back to reference Hillner BE, Siegel BA, Shields AF et al (2009) The impact of positron emission tomography (PET) on expected management during cancer treatment: findings of the National Oncologic PET Registry. Cancer 115:410–418, Erratum in: Cancer 115:1133PubMedCrossRef Hillner BE, Siegel BA, Shields AF et al (2009) The impact of positron emission tomography (PET) on expected management during cancer treatment: findings of the National Oncologic PET Registry. Cancer 115:410–418, Erratum in: Cancer 115:1133PubMedCrossRef
24.
go back to reference Facey K, Bradbury I, Laking G, Payne E (2007) Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol 11:iii–iv, xi–267 Facey K, Bradbury I, Laking G, Payne E (2007) Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol 11:iii–iv, xi–267
25.
go back to reference Långström B, Grahnen A, Honoré PH et al (2009) The risk of exaggerated risk aversion—a life and death struggle for molecular imaging. Eur J Nucl Med Mol Imaging 36:1693–1694PubMedCrossRef Långström B, Grahnen A, Honoré PH et al (2009) The risk of exaggerated risk aversion—a life and death struggle for molecular imaging. Eur J Nucl Med Mol Imaging 36:1693–1694PubMedCrossRef
28.
go back to reference European Association of Nuclear Medicine (2008) Official EANM Position: The medical use of radiopharmaceuticals up to 2025. An exploration of the future medical use of radioisotopes. A report written and translated by Technopolis Group, commissioned by the Dutch Ministry of Housing, Spatial Planning and the Environment (VROM), and supported by the Dutch Society of Nuclear Medicine (NVNG) under the lead of Dr. J.F. Verzijlbergen. Available via https://www.eanm.org/news/official_eanm_position.php?navId=658. Accessed 21 July 2010 European Association of Nuclear Medicine (2008) Official EANM Position: The medical use of radiopharmaceuticals up to 2025. An exploration of the future medical use of radioisotopes. A report written and translated by Technopolis Group, commissioned by the Dutch Ministry of Housing, Spatial Planning and the Environment (VROM), and supported by the Dutch Society of Nuclear Medicine (NVNG) under the lead of Dr. J.F. Verzijlbergen. Available via https://​www.​eanm.​org/​news/​official_​eanm_​position.​php?​navId=​658. Accessed 21 July 2010
29.
go back to reference Cuocolo A, Bretnach É (2010) Multimodality imaging in Europe: a survey by the European Association of Nuclear Medicine (EANM) and the European Society of Radiology (ESR). Eur J Nucl Med Mol Imaging 37:163–167PubMedCrossRef Cuocolo A, Bretnach É (2010) Multimodality imaging in Europe: a survey by the European Association of Nuclear Medicine (EANM) and the European Society of Radiology (ESR). Eur J Nucl Med Mol Imaging 37:163–167PubMedCrossRef
Metadata
Title
PET/CT without capacity limitations: a Danish experience from a European perspective
Authors
Poul Flemming Høilund-Carlsen
Oke Gerke
Mie Holm Vilstrup
Anne Lerberg Nielsen
Anders Thomassen
Søren Hess
Mette Høilund-Carlsen
Werner Vach
Henrik Petersen
Publication date
01-06-2011
Publisher
Springer-Verlag
Published in
European Radiology / Issue 6/2011
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-010-2025-y

Other articles of this Issue 6/2011

European Radiology 6/2011 Go to the issue